Table 2.
| Gene | Reference | Cell lines and tumor samples | More detailed explanation of re-expression |
|---|---|---|---|
|
APAF1 Apoptotoic protease activating factor 1 |
Soengas et al. 2001 [37] | 9 Melanoma Cell lines (SK-Mel 5,19, -28, -94, -103, -147, -197) | Recovery of APAF 1 expression after 5-Aza-d2C treatment |
|
APOD Apolipoprotein D |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
BST2 Bone marrow stromal cell antigen 2 |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
CAM Calmodulin |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 5 fold increase in expression after demythelation with 5-Aza-dC |
|
CCR-7 Chemokine receptor 7 |
Mori et al. 2005 [61] | 11 Melanoma Cell lines (MA-MK) | Upregulation of CCR-7 after treatment with 5-Aza-2dC and/or TSA |
|
CDH1 Cadherin 1 |
Paz et al. 2003 [34] | 18 Melanoma cell lines SK MEL2, -5, -19, -28, -29, -94, -100, -103, -147, -173, -187, -197, G-361, Malme-3M, M14-Mel, UACC-62, -257, LOX-LIVM |
Re-expression of CDH1 in 9/18 cell lines (50%), SK MEL19, -28, -103, -147, 1-73, -197, UACC62, LOX-LIVM |
|
CDKNA1 (p21) Cyclin-dependent Kinase Inhibitor 1A |
Halaban et al. 2009 [62] | 8 Melanoma cell strains YUMAC, YUSAC2, YULAC, YUSAIT, YUGEN8, WW 165, YURIF, 501 mel |
Significant increase in expression after treatment with 5-Aza-dC in all cell lines except YUSIT1 |
| Clu (Clusterin) | Halaban et al. 2009 [62] | 8 Melanoma cell strains YUMAC, YUSAC2, YULAC, YUSiIT1, YUGEN8, WW165, YURIF, 501 mel |
Significant increase in expression in all cell lines |
|
COL1A2 Collagen, type 1, alpha2 |
Koga et al. 2009 [112] | 2 Melanoma strains YUGEN8, YUMAC | > 400 fold increase in YUGEN8 and >500 fold increase in YUMAC after treatment with 5-Aza-dC |
|
CSK c-Src kinase |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
CSNK162 Casein kinase1 gamma2 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
CSPCB Cartilage-specific proteoglycan core protein |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
CYBA Cytochrome B, alpha subunit |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
DDIT4L DNA-Damage-Inducible Transcript 4- like |
Koga et al. 2009 [112] | 2 Melanoma strains YUGEN8, YUMAC | >200 fold increase in YUGEN8 and >400 fold increase in YUMAC after treatment with 5-Aza-dC |
|
EBP1 Cell cycle protein p38-2G4 homolog |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
EF1- alpha Elongation factor alpha |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
ET2 Endothelin 2 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 5 fold increase in expression after demythelation with 5-Aza-dC |
|
F6 ATP synthase coupling factor 6 mitochondrial |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
GARS Glycyl tRNA synthetase |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
GIP 3 Interferon-inducible peptide precursor |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
HSPB1 Heat-shock 27 KDA protein |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
HSBP6 Heat shock protein alpha-crystallin related B6 |
Koga et al. 2009 [112] | 2 Melanoma strains YUGEN8, YUMAC | >150 fold increase in YUGEN8 and >400 fold increase in YUMAC after treatment with 5-Aza-dC |
|
IFIT1 Interferon-induced protein with tetra- Tricopeptide repeats1 |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
ISGF3G Interferon-stimulated transcription factor3, gamma |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
ITGAE Integrin alpha E |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
| ITGB8 Integrin beta 8 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
| KIAA0324 | Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
LDHB L-Lactate dehydrogenase H subuint |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
MT1G Metallothionein |
Koga et al. 2009 [112] | 2 Melanoma strains YUGEN8, YUMAC | >50 fold increase in YUGEN8 and >200 fold increase in YUMAC after treatment with 5-Aza-dC |
|
MT2A Metallothionein 2A |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
MX1 Myxovirus resistance 1/interferon- inducible |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
NPM 2 Nucleoplasmin 2 |
Koga et al. 2009 [112] | 2 Melanoma strains YUGEN8, YUMAC | >150 fold increasein YUGEN8 and > 100 fold increase in YUMAC after treatment with 5-Aza-dC |
| P-Cadherin | Tsutsumida et al. 2004 [99] | Melanoma cell lines AKI and A375 | Re-expression after 5-Aza-dC treatment |
|
PCNA Proliferating cyclic nuclear antigen |
Van der Velden et al. 2003 | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
| PIRIN | Van der Velden et al. 2003 | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demythelation with 5-Aza-dC |
|
RAR-b2 Retinoic acis receptor b2 |
Paz et al.2003 [34] | 18 Melanoma cell lines SK MEL2, -5, -19, -28, -29, -94, -100, -103, -147, -173, -187, -197, G-361, Malme-3M, M14-Mel, UACC-62, -257, LOX-LIVM |
Re-expression after 5 Aza-dC treatment in 10/18 cell lines (56%), SK MEL 2, -5, -19, -28 -29, - 100, -173, -187, Malme3M, UACC-257 |
|
RASSF1 Ras Association domain Family protein 1 |
Paz et al. 2003 [34] | 18 Melanoma cell lines SK MEL2, -5, -19, -28, -29, -94, -100, -103, -147, -173, -187, -197, G-361, Malme-3M, M14-Mel, UACC-62, -257, LOX-LIVM |
Re-expression of RASF 1 protein after treatment with 5-Aza-dC in all Cell lines (100%) |
|
RGS3 Regulator of G-protein signaling 3 |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
RPL37A Ribosomal protein L37A |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
S100A1 S100 Calcium-binding protein A1 |
Gallaghar et al. 2005 [109] | 4 Melanoma Cell lines WM 793, -P2, P2; 1205- Lu |
Increase in Gene expression and reduction in cell growth after 5- Aza-dC Treatment |
|
SIAT4A Sialyltransferase 4A |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma cell line MEL-270 | 3 fold increase in expression after demethylation with 5-Aza-dC |
|
TIMP 3 Tissue inhibitor of metalloproteinase 3 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma cell line MEL-270 and metastatic uveal melanoma cell line OMM1.3 |
Methylation shown in both cell lines (100%), also 3 fold increase in expression after demythelation with 5-Aza-dC of MEL-270 |
|
TIMP1 Tissue inhibitor of metalloproteinase 1 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 3 fold increase in expression after demethylation with 5-Aza-dC |
|
TGFBI (transforming growth factor, beta-induced) |
Halaban et al. 2009 [62] | 8 Melanoma cell strains YUMAC, YUSAC2, YULAC, YUSAIT, YUGEN8, WW 165, YURIF, 501 mel |
Significant increase in all cell lines except WW165 |
|
TNFRSF10A (DR4, TRAIL-1) Tumor necrosis factor receptor superfamily, member 10a |
Bae et al. 2008 [91] | SK-Mel-28, SK-Mel-3 and 8 additional Melanoma cell lines (unspecified) | >3 fold increase in re-expression after treatment with 5-Aza-dC |
|
TRP-1 Tyrosine-related protein1 |
Van der Velden et al. 2003 [106] | Primary Uveal Melanoma Cell line MEL-270 | 5 fold increase in expression after demethylation with 5-Aza-dC |
|
TSP1 Thrombospondin 1 |
Paz et al. 2003 [34] | 18 Melanoma cell lines SK MEL2, -5, -19, -28, -29, -94, -100, -103, -147, -173, -187, -197, G-361, Malme-3M, M14-Mel, UACC-62, -257, LOX-LIVM |
Re-expression of TSP1 after treatment with 5-Aza-dC in all Cell lines (100%) |
|
WFDC WAP 4-disulfide core domain 1 |
Muthusamy et al. 2006 [20] | 9 Melanoma cell lines (MelJuSo, UACC 903, C8161, Neo6/C8161, WM1205 Lu, WM35, Roth, Carney, and WM455) 20 melanoma tumor samples |
5 fold increase in expression after demethylation with 5-Aza-dC |